Paul Grint

Dr. Paul Grint

Dr. Grint was most recently CEO and a member of the board of directors of AmpliPhi Biosciences which recently merged with C3J Therapeutics to form Armata Pharmaceuticals. Dr. Grint has more than two decades of experience in biologics and small molecule research and development, including the successful approval and commercialization of products in the infectious […]

Andrew Scott

Prof. Andrew Scott

Prof. Andrew Scott is Laboratory Head at the Olivia Newton-John Cancer Research Institute; Director, Department of Molecular Imaging and Therapy, Austin Health; and Professor, University of Melbourne, La Trobe University, and Monash University. His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies, and in molecular […]

Robert Ivkov

Dr. Robert Ivkov

Dr. Ivkov’s research focuses on the development and characterization of magnetic nanoparticles and AMF-devices for cancer therapy. Upon his arrival to the Department of Radiation Oncology and Molecular Radiation Sciences at The Johns Hopkins University School of Medicine in early 2008, Dr. Ivkov began a broad research program with the aim to develop clinical applications […]

Mark Van Asten

Mark Van Asten

Mark has over 30 years of experience in the medical diagnostics and life science industry. Much of this time has been specific to international business development, strategic planning and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of a number of innovative technology […]

melanie leydin headshot

Melanie Leydin CA FGIA

Melanie Leydin holds a Bachelor of Business majoring in Accounting and Corporate Law. Ms. Leydin is a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia, and is a Registered Company Auditor. Ms. Leydin graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and from February 2000 […]

David Ludvigson

David Ludvigson

David is currently CEO at Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new […]

Michael Harsh

Michael Harsh

Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare. As the Global Technology Leader of Imaging Technologies at GE Global Research, he led the research for X-Ray, CT, MRI, Ultrasound, Nuclear Medicine, PET and Optical Imaging, and the […]

Robert Proulx

Bob has served as Chairman of the Board at Imagion Biosystems since the company’s IPO in 2017. As President and CEO of Imagion Biosystems beginning in February 2015 until June 2023, he led the company developing the nanoparticle-based medical imaging technology from early proof of concept through initial clinical development until June 2023. Bob’s career […]